Mixed connective-tissue disease

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Mixed connective-tissue disease describes a recognisable overlap of systemic lupus, systemic sclerosis and inflammatory myopathy features in association with high-titre anti-U1-RNP. Raynaud phenomenon and puffy hands often appear early, followed by inflammatory arthritis, myositis, oesophageal dysfunction, sclerodactyly, serositis, cytopenia or pulmonary disease. Several proposed criteria sets exist, but none replaces expert clinical synthesis. Anti-U1-RNP is necessary to the concept but not sufficient because it also occurs in SLE and other conditions.

The diagnostic label should remain useful rather than restrictive. Some people preserve an overlap pattern for years; others meet criteria for a better-defined disease later. At each review, describe the actual active phenotype and organ risk. Anti-dsDNA with nephritis, RNA-polymerase-III with rapidly progressive skin disease, a myositis-specific antibody with rash and weakness, or an antisynthetase ILD pattern may redirect management even when anti-U1-RNP remains positive.

Cardiopulmonary surveillance is central. ILD and PAH are leading serious complications, and their symptoms overlap with reflux aspiration, myocarditis, deconditioning and respiratory muscle weakness. Baseline PFT with DLCO, HRCT based on phenotype, ECG, NT-proBNP and echocardiography create a comparison. Falling DLCO or unexplained dyspnoea triggers PAH screening and right-heart catheterisation where indicated. Muscle strength, CK and swallowing assessment are repeated when symptoms evolve.

Treatment follows the dominant manifestation rather than an MCTD-specific ladder. Vasodilators manage Raynaud; hydroxychloroquine can treat inflammatory skin or joints; methotrexate may support arthritis; mycophenolate is used for selected ILD and organ disease; severe myositis or serositis may need glucocorticoid and steroid-sparing therapy. Systemic-sclerosis features change steroid safety. Pregnancy is planned during stability after defining anti-Ro, anti-La and antiphospholipid antibodies and converting incompatible medicines.

Key points

MCTD is a clinical overlap syndrome associated with persistent high-titre anti-U1-RNP; the antibody alone, especially a low or isolated laboratory result, does not establish disease.
Typical early features include Raynaud phenomenon, puffy hands, inflammatory polyarthritis, myalgia or myositis and later scleroderma, lupus, pulmonary or oesophageal manifestations.
No universally accepted diagnostic criteria exist for routine care; specialist diagnosis integrates phenotype, anti-U1-RNP, exclusion of mimics and longitudinal evolution.
At baseline examine skin, nailfolds, joints and muscle strength and assess FBC, renal and urine, CK, ECG, echocardiography, pulmonary function including DLCO and HRCT when respiratory risk exists.
Screen repeatedly for PAH because exertional symptoms or isolated DLCO decline can precede right-heart failure; suspected disease requires right-heart catheterisation before PAH-specific therapy.
Distinguish ILD, PAH, aspiration, infection, heart disease and respiratory muscle weakness rather than treating all breathlessness as one autoimmune lung problem.
Treat the dominant organ according to the best-supported systemic sclerosis, SLE, myositis, ILD or pulmonary-hypertension pathway; there is no single medicine regimen for the MCTD label.
Hydroxychloroquine may support inflammatory joints or skin, methotrexate selected musculoskeletal disease and mycophenolate ILD or major-organ disease; all are specialist choices with indication-specific monitoring.
Use glucocorticoid cautiously when a scleroderma phenotype or renal-crisis risk is present, while severe myositis or organ inflammation may still require prompt supervised treatment.
Reassess classification over time and before pregnancy because new renal, skin, muscle, antibody or pulmonary features can change treatment and fetal risk.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Autoimmune genetic susceptibility

Polygenic HLA and immune-regulatory susceptibility permits loss of tolerance to ribonucleoprotein antigens; environmental influences likely modify expression but no single cause is established.

Anti-U1-RNP-associated phenotype

Persistent high-titre anti-U1-RNP accompanies a characteristic overlap of Raynaud, puffy hands, arthritis, myositis, scleroderma and lupus-like features.

Dynamic disease classification

Some patients retain a mixed phenotype while others evolve toward systemic sclerosis, lupus, inflammatory myopathy or another defined connective-tissue disease over time.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Ribonucleoprotein autoimmunity
B- and T-cell responses to U1 small nuclear ribonucleoprotein generate high-titre antibodies and immune activation across vascular, synovial, muscle and lung tissues.
2
Small-vessel vasculopathy
Endothelial dysfunction and vasospasm produce Raynaud phenomenon, nailfold change and digital injury and can progress to pulmonary arteriolar remodelling.
3
Inflammatory overlap injury
Synovitis, myositis, serositis and immune blood-cell changes resemble lupus or inflammatory myopathy and may respond to immunosuppression.
4
Fibrotic cardiopulmonary disease
Repeated lung and vascular injury can lead to ILD, PAH and myocardial involvement, which determine prognosis more than antibody titre or label.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Raynaud and puffy hands

Episodic colour change with persistent oedematous fingers and abnormal nailfolds is a common early clue before fixed sclerodactyly develops.

Inflammatory musculoskeletal overlap

Symmetrical synovitis, tendon inflammation, myalgia and objective proximal weakness can coexist, requiring separate joint and muscle activity measurement.

Pulmonary vascular signalRed flag

Exertional syncope, chest pain, disproportionate DLCO fall, raised NT-proBNP or right-heart findings suggests PAH and warrants urgent evaluation.

Interstitial lung signalRed flag

Dry cough, crackles, restriction, falling DLCO or HRCT NSIP indicates ILD, while rapid hypoxia raises infection and inflammatory progression.

Oesophageal and bulbar disease

Reflux and dysmotility can mimic myositis dysphagia; nasal speech, weak neck flexion and aspiration support bulbar muscle involvement.

Phenotype evolution

New nephritis, dermatomyositis rash, progressive skin thickening, digital ulcer or disease-specific antibody can supersede an earlier undifferentiated overlap formulation.

Red flags requiring action

Exertional syncope, chest pain, falling DLCO, raised NT-proBNP or right-heart signs may indicate pulmonary arterial hypertension and requires rapid haemodynamic assessment.
Rapidly worsening cough, breathlessness, oxygen need or new ground-glass opacity may reflect inflammatory ILD, infection, aspiration, haemorrhage or oedema.
Dysphagia, weak cough, neck flexor weakness, declining vital capacity or aspiration suggests bulbar or respiratory muscle involvement.
New hypertension and renal dysfunction is atypical enough to prompt assessment for scleroderma renal crisis, lupus nephritis, TMA and medicine toxicity.
A hot joint, fever, neutropenia or focal infection during immunosuppression must be treated as possible sepsis rather than assumed overlap flare.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
ANA pattern, anti-U1-RNP and phenotype-directed antibodiesFirst step
Why
Support the mixed phenotype and identify evidence for an evolving defined connective-tissue disease.
Interpretation and limitations
Persistent high-titre anti-U1-RNP is characteristic but not diagnostic alone; interpret anti-dsDNA, Sm, Ro, La, SSc and myositis antibodies against clinical findings.
02
FBC, renal, liver, CK, ESR or CRP and urinalysis
Why
Establish systemic activity, muscle injury, organ baseline and treatment safety.
Interpretation and limitations
Normal CK does not exclude all myositis; protein or blood in urine is atypical enough to trigger SLE, TMA and other renal evaluation.
03
Pulmonary function including DLCO
Why
Measure restrictive, gas-transfer and respiratory-muscle consequences and track change.
Interpretation and limitations
FVC decline supports ILD progression; isolated or disproportionate DLCO decline raises PAH, anaemia and emphysema.
04
HRCT chest
Why
Define ILD pattern and extent when baseline phenotype or respiratory change indicates imaging.
Interpretation and limitations
NSIP is frequent, but aspiration, infection, oedema, organising pneumonia and established fibrosis need multidisciplinary distinction.
05
ECG, NT-proBNP and echocardiography
Why
Screen cardiac involvement and estimate pulmonary-hypertension probability.
Interpretation and limitations
A concerning composite leads to specialist right-heart catheterisation; echocardiography alone cannot establish haemodynamic type.
06
Right-heart catheterisation
Why
Confirm pulmonary hypertension and separate pre-capillary PAH from left-heart or lung-disease mechanisms.
Interpretation and limitations
This is the haemodynamic reference standard before PAH-specific treatment and provides pressure, wedge and vascular-resistance measurements.
07
Muscle MRI, EMG, biopsy and swallow testing
Why
Confirm inflammatory myopathy or bulbar dysfunction when weakness is objective or unexplained.
Interpretation and limitations
Select tests with neuromuscular expertise; MRI guides biopsy, EMG identifies mimics and videofluoroscopy or FEES defines aspiration risk.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Systemic lupus erythematosus

Immune-complex nephritis, anti-dsDNA, anti-Sm and low complement with lupus criteria may indicate SLE despite anti-U1-RNP positivity.

Systemic sclerosis

Progressive skin thickening, scleroderma capillaries, anti-centromere, anti-topoisomerase-I or anti-RNA-polymerase-III and organ vasculopathy may support systemic sclerosis.

Inflammatory myopathy or antisynthetase

Dominant weakness, dermatomyositis rash, muscle-specific antibodies or ILD with antisynthetase features may justify a myositis-spectrum diagnosis and pathway.

Undifferentiated connective-tissue disease

Autoimmune symptoms and ANA without the characteristic high-titre anti-U1-RNP overlap phenotype may remain undifferentiated during longitudinal assessment.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01Diagnostic synthesisConfirm overlap without antibody anchoringFirst stepRaynaud, puffy hands, arthritis, weakness or systemic findings accompany anti-U1-RNP.

1Map skin, capillaries, joints, strength, swallowing, heart, lungs, renal and neurological systems and document the temporal sequence.
2Confirm anti-U1-RNP and request only phenotype-directed lupus, scleroderma, myositis and APS tests with baseline blood, urine, PFT and cardiac screening.
3AlternativeExclude infection, medicine effects and alternative CTD, then record the active organ phenotype and what future findings would change classification.

02Cardiopulmonary screeningSeparate ILD from pulmonary vascular diseaseMCTD is established or respiratory symptoms, DLCO or examination changes.

1Obtain PFT with DLCO, oxygen assessment and HRCT for ILD risk, plus ECG, NT-proBNP and echocardiography for vascular or cardiac risk.
2Discuss imaging and physiology jointly; investigate infection, aspiration, embolism, anaemia, myocarditis and muscle weakness as competing or additive causes.
3Arrange right-heart catheterisation for a concerning PAH screen and refer progressive ILD to respiratory-rheumatology multidisciplinary care.

03Organ-directed treatmentTreat the active phenotypeObjective inflammatory or vascular disease produces symptoms, tissue risk or functional decline.

1Use warming and nifedipine for uncomplicated Raynaud, hydroxychloroquine for suitable inflammatory skin or joints and methotrexate for selected persistent arthritis.
2Use mycophenolate or another specialist regimen for ILD or major-organ inflammation, and PAH-specific combinations only after haemodynamic confirmation.
3If glucocorticoid is needed for myositis or severe inflammation, use a defined taper and monitor pressure and kidneys closely when scleroderma features are present.

04Longitudinal reclassificationLet new evidence change the labelNew organ disease, rash, antibodies or treatment response alters the previous overlap picture.

1Reassess current SLE, systemic-sclerosis, myositis and antisynthetase criteria without assuming anti-U1-RNP makes them mutually exclusive.
2Update organ-specific surveillance and treatment when a more precise diagnosis or complication emerges, communicating the change across teams.
3Before pregnancy confirm stability, renal and cardiopulmonary risk, anti-Ro, anti-La and aPL and change incompatible medicines in advance.

Key medicines and prescribing safety5 treatments · regimens, roles and cautions

Controls lupus-like cutaneous or musculoskeletal activity and may reduce reliance on glucocorticoid.

Hydroxychloroquine

For selected inflammatory skin or joint disease use 200–400 mg orally daily, not exceeding 5 mg/kg actual body weight/day, at the lowest effective dose.

It does not treat PAH or established ILD fibrosis. Review renal function, maculopathy, QT interactions, hypoglycaemia and cardiomyopathy and arrange risk-based retinal monitoring; it is pregnancy-compatible under BSR guidance.

First oral vasodilator for troublesome Raynaud in a scleroderma-spectrum vascular phenotype.

Nifedipine modified release

Start 30 mg orally once daily for Raynaud phenomenon and increase, commonly to 60 mg once daily, according to response and blood pressure.

Monitor headache, flushing, tachycardia, oedema, reflux and symptomatic hypotension and review interacting CYP3A4 medicines; critical ischaemia needs urgent specialist escalation rather than slow outpatient titration.

Steroid-sparing conventional treatment for articular or selected cutaneous disease when lung and reproductive factors permit.

Methotrexate with folic acid

For persistent inflammatory arthritis, specialists commonly start 7.5–15 mg orally or subcutaneously once weekly with folic acid at least 5 mg on another day, then titrate according to response.

Never dose daily. Monitor FBC, liver and renal function, avoid trimethoprim or co-trimoxazole and review pre-existing ILD. Stop at least one month before maternal conception and avoid in pregnancy.

Steroid-sparing immunomodulation for inflammatory or progressive lung and overlap organ disease.

Mycophenolate mofetil

For selected ILD or major-organ disease, start 500 mg orally twice daily and titrate toward 1 g twice daily, sometimes 1.5 g twice daily, under specialist response and toxicity monitoring.

Monitor FBC, liver and renal function, infection and gastrointestinal effects. It is a major teratogen requiring pregnancy exclusion, contraception and planned substitution before conception.

Provides rapid control of active muscle or selected systemic inflammation while definitive therapy becomes effective.

Prednisolone for myositis

For clinically significant inflammatory myopathy a specialist may use 0.5–1 mg/kg orally once daily, with intravenous rescue for bulbar or respiratory threat and an early steroid-sparing taper.

Exclude infection, monitor muscle function rather than CK alone and protect bone, glucose, mood and stomach where indicated. Scleroderma features increase renal-crisis concern, so exposure needs explicit justification and pressure monitoring.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Pulmonary arterial hypertension

Progressive pulmonary vascular disease causes exertional intolerance, syncope, right-heart failure and premature death and can be disproportionate to ILD extent.

Interstitial lung disease

Inflammatory or fibrotic NSIP and other patterns reduce lung volumes and gas transfer, with aspiration and muscle weakness compounding respiratory limitation.

Myositis and swallowing failure

Proximal and bulbar muscle inflammation causes falls, aspiration, malnutrition and ventilatory failure if weakness is not measured and treated.

Treatment and classification harm

Infection, cytopenia, teratogenicity and organ toxicity coexist with the risk of applying one label so rigidly that evolving organ-specific disease is missed.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

At each review record the dominant phenotype, new classification features, Raynaud or ulcers, joints, strength, swallowing, lungs, heart, pressure and urine.
Repeat PFT with DLCO every three to six months during early or changing lung disease and use HRCT for a clinical question rather than automatic radiation.
Perform at least annual PAH screening, more often with symptoms or gas-transfer decline, and document who owns right-heart catheter referral.
Monitor CK, strength and function together because enzyme and disability trajectories can diverge; add swallowing or respiratory testing when bulbar symptoms appear.
Apply medicine-specific blood, retinal, infection and reproductive safety schedules and verify vaccines before major immunosuppression.
Revisit contraception and pregnancy intentions, anti-Ro or anti-La and aPL status and maternal cardiopulmonary risk before conception.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Anti-U1-RNP is not a diagnosis

The result gains meaning from titre, assay and a characteristic overlap phenotype and also occurs in established SLE.

The dominant organ owns treatment

A PAH regimen follows haemodynamics, an ILD regimen follows behaviour and myositis treatment follows weakness, irrespective of the umbrella label.

Labels can mature

Longitudinal reclassification is accurate medicine, not diagnostic failure, when a previously mixed phenotype develops specific organ and antibody evidence.

DLCO is a fork, not an answer

A fall may reflect pulmonary vascular disease, ILD, anaemia or emphysema and should trigger separation of these mechanisms.

Steroid rules differ across the overlap

A dose appropriate for severe myositis can endanger a scleroderma renal-crisis phenotype, requiring careful multidisciplinary balance.

11Common pitfallsFrequent interpretation and management errors.

01
Diagnosing MCTD from an isolated anti-U1-RNP result without objective overlap manifestations.
02
Using the MCTD label to avoid screening separately for ILD, PAH, myositis and renal disease.
03
Calling worsening breathlessness ILD without assessing pulmonary hypertension, aspiration, infection, heart disease and muscle weakness.
04
Applying a standard high-dose glucocorticoid regimen without considering systemic-sclerosis renal-crisis risk.
05
Repeating antibody titres as the main activity measure while organ physiology deteriorates.
06
Refusing to reclassify evolving lupus, systemic sclerosis, antisynthetase or myositis disease because the original label persists.